Affinage

PIAS1

E3 SUMO-protein ligase PIAS1 · UniProt O75925

Length
651 aa
Mass
71.8 kDa
Annotated
2026-06-10
100 papers in source corpus 53 papers cited in narrative 53 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PIAS1 is a nuclear SUMO E3 ligase that controls gene expression and genome integrity by both catalytic SUMO conjugation of diverse substrates and non-enzymatic protein interactions, and it acts as a central negative regulator of inflammatory and innate-immune transcription (PMID:9724754, PMID:15311277, PMID:11583632). Its founding activity is selective repression of cytokine-inducible transcription: PIAS1 docks onto activated, tyrosine-phosphorylated STAT1 dimers through its C-terminal domain binding the STAT1 N-terminal region and blocks STAT1 DNA binding, while in vivo a subset of IFN-inducible genes is derepressed in Pias1-null cells with increased STAT1 promoter recruitment (PMID:9724754, PMID:10805787, PMID:15311277). In parallel it represses NF-κB by binding nuclear p65 and blocking its DNA binding (PMID:15657437). As a RING-type SUMO E3 ligase, PIAS1 binds Ubc9 and SUMO and conjugates SUMO to a broad substrate spectrum—p53, Sp3, androgen receptor, FAK, p73, RUNX proteins, MYC, PML, vimentin, and PCNA—to control substrate activity, localization, or proteasomal turnover, often by priming substrates for STUbL (RNF4)-dependent degradation (PMID:11583632, PMID:12356736, PMID:12177000, PMID:27239040, PMID:25895136, PMID:26450775, PMID:30487218, PMID:32047143). PIAS1 functions in DNA repair, being recruited via its SAP domain to double-strand breaks where it drives SUMO accumulation and the productive assembly of 53BP1, BRCA1, and RNF168, and it promotes PCNA Lys-164 sumoylation required for error-free template-switch damage tolerance (PMID:20016603, PMID:30487218). Structurally, its N-terminal SAP domain forms a four-helix bundle that binds A/T-rich DNA and substrates, and PIAS1 forms a non-covalent ternary complex with SUMO1 and UBC9 required for transcriptional repression (PMID:15133049, PMID:24174529). Its activity is tuned by post-translational modification—IKKα-mediated Ser90 phosphorylation enabling NF-κB repression and PRMT1-mediated Arg303 methylation enabling late-phase STAT1 repression (PMID:17540171, PMID:19136629). PIAS1 additionally restricts viral replication (HSV-1, EBV, influenza A) and modulates Huntingtin sumoylation and aggregation in models of Huntington's disease (PMID:27099310, PMID:35377920, PMID:23871671, PMID:27146268).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1998 High

    Established PIAS1's founding function by showing it selectively represses STAT1-dependent transcription, defining a paradigm of inhibitor of activated STAT.

    Evidence Co-IP, DNA binding and reporter assays in cytokine-stimulated cells

    PMID:9724754

    Open questions at the time
    • Did not resolve the structural basis of the STAT1 interaction
    • Mechanism of selectivity for STAT1 over STAT2/3 unexplained
  2. 2000 High

    Mapped the interaction to PIAS1 C-terminus binding STAT1 N-terminus and showed PIAS1 selectively recognizes STAT1 dimers, explaining how repression is coupled to activation.

    Evidence Yeast two-hybrid, in vitro binding, domain deletion, dimer/monomer discrimination

    PMID:10805787

    Open questions at the time
    • No structure of the PIAS1–STAT1 complex
    • How dimer recognition prevents DNA binding not shown at atomic level
  3. 2001 High

    Defined PIAS1 as a bona fide SUMO E3 ligase by reconstituting Ubc9-dependent p53 sumoylation and showing RING-domain dependence, transforming it from a STAT inhibitor into an enzyme.

    Evidence In vitro and cell-based SUMOylation assays with RING-domain mutagenesis

    PMID:11583632

    Open questions at the time
    • Functional consequence of p53 sumoylation not fully resolved here
    • Substrate range unknown at the time
  4. 2002 High

    Extended the ligase function to transcription factors (Sp3, AR), establishing that PIAS1-mediated sumoylation silences transcriptional activity without altering DNA binding, and identified a RING-independent p53 coactivator role.

    Evidence In vitro/in vivo sumoylation, mutagenesis, reporter assays, Co-IP

    PMID:11788578 PMID:12177000 PMID:12356736

    Open questions at the time
    • Whether sumoylation versus binding drives each transcriptional outcome not cleanly separated
    • Endogenous substrate-specificity determinants unmapped
  5. 2003 High

    Showed sumoylation can activate rather than silence a substrate, with FAK sumoylation at Lys-152 driving nuclear localization and autophosphorylation, broadening the functional outcomes of PIAS1 catalysis.

    Evidence Co-IP, in vitro binding, cell-based sumoylation, kinase assays, fractionation

    PMID:14500712

    Open questions at the time
    • Physiological context of nuclear FAK function unclear
    • Downstream nuclear FAK targets not defined
  6. 2004 High

    Demonstrated PIAS1 is physiologically required to restrain innate immunity in vivo and resolved the SAP-domain four-helix-bundle structure that binds A/T-rich DNA, linking chromatin association to function.

    Evidence Pias1-/- mice, ChIP, gene expression; NMR structure with DNA/p53 binding assays

    PMID:15133049 PMID:15311277 PMID:15572666 PMID:15572677

    Open questions at the time
    • How the SAP domain selects specific promoters in vivo not fully established
    • Genome-wide direct targets not defined at this stage
  7. 2005 High

    Generalized the transcriptional-repressor role beyond STAT1 to NF-κB p65 and revealed context-dependent coactivator functions (SRF-driven smooth muscle genes), establishing PIAS1 as a bidirectional transcriptional regulator.

    Evidence Pias1-/- mice, Co-IP, DNA binding, ChIP; mammalian two-hybrid and SRF-/- cells

    PMID:15657437 PMID:16135793 PMID:16144832

    Open questions at the time
    • What dictates repressor versus coactivator behavior unclear
    • Promoter-context determinants of selectivity unresolved
  8. 2007 High

    Identified phosphorylation as the activating signal, with IKKα phosphorylating Ser90 to license NF-κB repression and promoter recruitment, integrating PIAS1 into proinflammatory signaling kinetics.

    Evidence Phospho-mutant analysis, Co-IP, ChIP in TNF/LPS-stimulated cells

    PMID:17440973 PMID:17540171

    Open questions at the time
    • Structural effect of Ser90 phosphorylation unknown
    • Whether phosphorylation alters catalytic versus binding activity not separated
  9. 2009 High

    Showed arginine methylation at Arg303 by PRMT1 is required for late-phase STAT1 repression and defined PIAS1 recruitment to DSBs via its SAP domain, coupling it to SUMO-driven DNA repair factor assembly.

    Evidence In vitro methylation, MS, mutagenesis, ChIP; laser micro-irradiation, SAP mutants, epistasis

    PMID:19136629 PMID:19620279 PMID:20016603

    Open questions at the time
    • How methylation and phosphorylation are coordinated unknown
    • Direct DSB-site SUMO substrates of PIAS1 not all defined
  10. 2010 High

    Linked PIAS1 to epigenetic gene silencing and lineage control by showing it maintains repressive chromatin at the Foxp3 promoter and modulates developmental signaling (Hedgehog/Gli, TGFβ/SnoN), expanding its role to chromatin and differentiation.

    Evidence Pias1-/- mice, ChIP, bisulfite sequencing; in vivo neural tube and EMT assays

    PMID:20421208 PMID:20711444 PMID:20966256 PMID:21103059

    Open questions at the time
    • Direct versus indirect chromatin recruitment not fully separated
    • How DNMT/HP1 recruitment is targeted unresolved
  11. 2013 High

    Defined the SUMO–UBC9–PIAS1 ternary complex required for repression and connected PIAS1 to neurodegeneration by identifying it as the HTT SUMO ligase regulating insoluble HTT accumulation.

    Evidence NMR/ITC/BRET biophysics; E3 ligase screen, gain/loss-of-function, Drosophila HD model

    PMID:23871671 PMID:23938469 PMID:24061474 PMID:24174529

    Open questions at the time
    • In vivo relevance of the ternary complex to specific substrates untested
    • Mechanism converting HTT sumoylation to insolubility unclear
  12. 2014 Medium

    Mapped PIAS1 genome-wide as a chromatin-bound AR coregulator and established it as the MYC/c-Myc SUMO ligase controlling MYC stability and oncogenic activity, embedding it in cancer-relevant transcription programs.

    Evidence ChIP-seq, RNAi, transcriptomics; Co-IP, sumoylation, MYC turnover/phospho analysis, MS

    PMID:24777122 PMID:25031400 PMID:25552417 PMID:25895136 PMID:27239040

    Open questions at the time
    • Causal contribution of individual substrate sumoylations to tumorigenesis not isolated
    • Cooperation with FOXA1/pioneer factors mechanistically incomplete
  13. 2016 High

    Demonstrated in vivo therapeutic relevance in Huntington's disease, where striatal PIAS1 knockdown reduces mHTT accumulation and improves behavior, and showed PIAS1 restricts HSV-1 at PML nuclear bodies.

    Evidence In vivo miRNA knockdown in R6/2 mice; IF localization, SIM mutants, viral replication assays

    PMID:24911587 PMID:27099310 PMID:27146268 PMID:29262325

    Open questions at the time
    • Substrate(s) mediating the HD benefit not pinned to a single target
    • How PML-body localization is regulated dynamically unclear
  14. 2018 High

    Established PIAS1 (with PIAS4) as the physiological SUMO ligase for PCNA Lys-164 required for error-free template-switch damage tolerance, giving it a defined genome-maintenance substrate by clean genetic epistasis.

    Evidence PIAS1/PIAS4 knockout cells, Ig conversion assay, PCNA sumoylation, epistasis, chimera rescue

    PMID:30487218

    Open questions at the time
    • Relative substrate division of labor between PIAS1 and PIAS4 not resolved
    • Regulation of recruitment to replication-associated lesions unclear
  15. 2020 High

    Used quantitative SUMO proteomics to define a broad PIAS1 substrate landscape including vimentin, whose sumoylation regulates intermediate-filament dynamics and migration, framing PIAS1 as a global cytoskeletal and signaling SUMO regulator.

    Evidence SILAC SUMO proteomics, in vivo sumoylation, VIM site mutagenesis, migration assays; SnoN/TIF1γ organoid study

    PMID:32047143 PMID:32770107

    Open questions at the time
    • Most of the 62 putative substrates lack functional validation
    • How substrate selectivity is achieved genome-wide unknown
  16. 2022 High

    Consolidated PIAS1 as a broad antiviral restriction factor by showing it sumoylates and destabilizes influenza A PB2 and the m6A reader YTHDF2 to limit IAV and EBV replication, with ligase activity required.

    Evidence Co-IP, CRISPR KO, ligase-dead mutants, RNP/stability assays, in vivo mouse IAV model

    PMID:34187905 PMID:35377920 PMID:38236021

    Open questions at the time
    • Breadth of antiviral substrate targeting across virus families incomplete
    • How host SUMO machinery is mobilized during infection unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how PIAS1 achieves substrate and promoter selectivity in vivo—how its post-translational modifications, SAP-domain DNA binding, and SIM-mediated localization are integrated to choose targets among its hundreds of potential substrates.
  • No unifying model linking PIAS1 modification state to substrate choice
  • Structural basis of substrate discrimination beyond STAT1 unknown
  • Functional validation lacking for most proteomically identified substrates

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0098772 molecular function regulator activity 4 GO:0140110 transcription regulator activity 4 GO:0016874 ligase activity 3 GO:0003677 DNA binding 2
Localization
GO:0005634 nucleus 4 GO:0000228 nuclear chromosome 2
Pathway
R-HSA-392499 Metabolism of proteins 5 R-HSA-1643685 Disease 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-168256 Immune System 3 R-HSA-73894 DNA Repair 2
Partners
FOXA1IKBKAPMLPRMT1RELASTAT1TP53UBC9
Complex memberships
CP2c/CP2b hexameric DNA-binding complexPIAS1-SUMO1-UBC9 ternary complexPNKP transcription-coupled repair complexSLX4 complex (via SLX4IP)

Evidence

Reading pass · 53 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 PIAS1 specifically inhibits STAT1-mediated gene activation by blocking the DNA binding activity of Stat1; PIAS1 physically associates with Stat1 (but not Stat2 or Stat3) after cytokine stimulation, and this interaction requires Stat1 phosphorylation on Tyr-701. Coimmunoprecipitation, DNA binding assays, reporter gene assays, yeast two-hybrid Proceedings of the National Academy of Sciences of the United States of America High 9724754
2000 The COOH-terminal domain of PIAS1 (aa 392–541) directly interacts with the NH2-terminal domain of Stat1 (aa 1–191), and PIAS1 specifically recognizes the dimeric form of Stat1 rather than the monomer; the NH2-terminal region of PIAS1 acts as a modulatory domain preventing interaction with Stat1 monomers. Yeast two-hybrid, in vitro binding assays, domain deletion mutants, modified yeast two-hybrid for dimer vs. monomer discrimination Proceedings of the National Academy of Sciences of the United States of America High 10805787
2001 PIAS1 functions as a SUMO E3 ligase for p53: it binds SUMO-1 and Ubc9 (the E2), catalyzes p53 sumoylation in vitro and in cells, and a RING finger-like domain mutation abolishes Ubc9 binding and ligase activity while retaining p53/SUMO-1 binding. Yeast two-hybrid, in vitro SUMOylation assay, cell-based SUMOylation assay, RING domain mutagenesis Molecular cell High 11583632
2002 PIAS1 acts as a SUMO E3 ligase for the transcription factor Sp3, stimulating SUMO conjugation at a single lysine in the IKXE motif; PIAS1 interacts with both Sp3 and Ubc9, and SUMO modification of Sp3 silences its transcriptional activity without altering DNA-binding specificity or affinity. In vitro and in vivo SUMOylation assays, mutagenesis, GST pulldown, reporter assays The EMBO journal High 12356736
2002 PIAS1 (and PIASxα) act as SUMO E3 ligases for the androgen receptor (AR), enhancing AR sumoylation in an RING finger-like domain-dependent manner; ligand (testosterone) binding to AR is required for sumoylation in intact cells, and PIAS1-mediated sumoylation represses AR-dependent transcription. Cell-based and in vitro SUMOylation assays, RING domain mutagenesis, reporter gene assays The Journal of biological chemistry High 12177000
2002 PIAS1 activates p53-mediated transcription independently of its RING finger (sumoylation) domain; PIAS1 interacts with the tetramerization and C-terminal regulatory domains of p53, and endogenous PIAS1 co-immunoprecipitates with endogenous p53. Yeast two-hybrid, coimmunoprecipitation, reporter gene assays, RING domain deletion mutant The Journal of biological chemistry Medium 11788578
2003 PIAS1 interacts with and sumoylates focal adhesion kinase (FAK) at Lys-152; sumoylation promotes FAK nuclear localization and dramatically increases FAK autophosphorylation at Tyr-397 in intact cells and in kinase assays, independently of cell adhesion. Yeast two-hybrid, in vitro binding, coimmunoprecipitation, cell-based SUMOylation, kinase assays, mutagenesis, subcellular fractionation The Journal of biological chemistry High 14500712
2004 PIAS1 sumoylates p73α (but not C-terminally truncated isoforms p73β and p73γ) through its RING finger domain; PIAS1 binding stabilizes p73, sumoylated p73 is restricted to the nuclear matrix, PIAS1-mediated sumoylation decreases p73 transcriptional activity, and PIAS1 overexpression reduces cells in G1 via reduced p21 transcription whereas PIAS1 siRNA causes G2 arrest. Yeast two-hybrid, pulldown, coimmunoprecipitation, cell-based SUMOylation, reporter assays, RNAi, cell cycle analysis Molecular and cellular biology High 15572666
2004 NMR structure of the N-terminal domain (residues 1–65) of PIAS1 revealed a four-helix SAP domain; this domain binds p53 (GST pulldown) and has strong affinity toward A/T-rich DNA, with the binding site mapping to one end of the four-helix bundle fitting the minor groove. NMR spectroscopy, GST pulldown, gel mobility shift assay The Journal of biological chemistry High 15133049
2004 PIAS1 is required for the innate immune response in vivo: Pias1−/− cells show that PIAS1 selectively inhibits a subset of IFN-γ– or IFN-β–inducible genes by interfering with STAT1 recruitment to gene promoters; Pias1−/− mice exhibit enhanced antiviral activity and increased protection against pathogenic infection. Knockout mouse (Pias1−/−), chromatin immunoprecipitation, gene expression analysis Nature immunology High 15311277
2004 SNM1A physically interacts with PIAS1 and they colocalize at nuclear foci; point mutations in the SNM1 domain that disrupt PIAS1 interaction cause mislocalization of SNM1A and loss of complementation of ICL repair defects, demonstrating PIAS1 interaction is required for SNM1A-mediated DNA interstrand cross-link repair. Coimmunoprecipitation, colocalization, mutagenesis, genetic complementation in DT40 cells Molecular and cellular biology Medium 15572677
2005 PIAS1 negatively regulates NF-κB signaling: upon cytokine stimulation, the p65 subunit of NF-κB translocates to the nucleus where it interacts with PIAS1; PIAS1 blocks p65 DNA binding activity in vitro and in vivo, and Pias1−/− cells show increased p65 occupancy at NF-κB target gene promoters. Knockout mouse, coimmunoprecipitation, in vitro DNA binding assay, chromatin immunoprecipitation, microarray Molecular and cellular biology High 15657437
2005 PIAS1 interacts with and sumoylates metabotropic glutamate receptor 8 (mGluR8) C-terminal domain; PIAS1 binding requires a region N-terminal to the consensus sumoylation motif and sumoylation occurs at Lys-882 within that motif in HEK293 cells. Yeast two-hybrid, GST pulldown, cell-based SUMOylation, mutagenesis The Journal of biological chemistry Medium 16144832
2005 PIAS1 activates smooth muscle cell differentiation marker genes (SM α-actin, SM MHC, SM22α) by interacting with serum response factor (SRF) and class I bHLH proteins (E2-2, E12); PIAS1 is required for SRF binding to the SM α-actin promoter in intact chromatin, and its effect requires SRF. Yeast two-hybrid, mammalian two-hybrid, coimmunoprecipitation, reporter assays, RNAi, chromatin immunoprecipitation, SRF−/− embryonic stem cells Molecular and cellular biology High 16135793
2006 PIAS1 confers DNA-binding specificity on the Msx1 homeoprotein by regulating its subnuclear localization to the nuclear periphery; interaction with PIAS1 (not sumoylation per se) is required for Msx1 to repress myogenic genes (MyoD, Myf5) and inhibit myoblast differentiation; myogenic regulatory genes repressed by Msx1 also localize at the nuclear periphery. Coimmunoprecipitation, live imaging, subnuclear localization assays, mutagenesis, reporter assays, RNAi Genes & development High 16600910
2007 Proinflammatory stimuli (TNF, LPS) induce IKKα-mediated phosphorylation of PIAS1 at Ser90; this phosphorylation is required for PIAS1 to repress NF-κB target gene transcription and for its rapid recruitment to NF-κB target gene promoters; IKKα (but not IKKβ) interacts with PIAS1 in vivo and mediates this phosphorylation in a SUMO ligase-dependent manner. Phospho-specific mutants (Ser90A), coimmunoprecipitation, chromatin immunoprecipitation, in vivo interaction assays Cell High 17540171
2007 PIAS1 interacts with and represses SOX9 transcriptional activity; PIAS1 enhances SUMOylation of SOX9 at Lys-396, and sumoylated SOX9 has reduced transcriptional activity on reporter constructs; PIAS1 can also repress SUMOylation-deficient SOX9-K396R, indicating additional SUMO ligase-dependent mechanisms. GST pulldown, coimmunoprecipitation, colocalization in tissue culture and mouse embryos, reporter assays, mutagenesis Molecular reproduction and development Medium 17440973
2007 PIAS1 and GATA-3 interact in Th2 cells; PIAS1 functions as a positive transcriptional coregulator for GATA-3 and facilitates GATA-3 recruitment to the IL-13 promoter, enhancing IL-13 expression in a promoter-selective manner. Coimmunoprecipitation, ChIP, reporter assays, siRNA knockdown, gain-of-function overexpression Journal of immunology Medium 18056374
2009 PRMT1 arginine-methylates PIAS1 at Arg-303 in vitro and in vivo upon IFN treatment; methylation-deficient and methylation-mimicking mutants show that this modification is essential for PIAS1 to be recruited to STAT1 target gene promoters in the late IFN response phase, leading to STAT1 release and transcriptional repression. In vitro methylation assay, mass spectrometry of methylation sites, mutagenesis, chromatin immunoprecipitation, RNAi Genes & development High 19136629
2009 SOCS1, SOCS3, and PIAS1 each promote myogenic differentiation by inhibiting the LIF-induced JAK1/STAT1/STAT3 pathway via distinct targets; PIAS1 targets activated STAT1 and prevents its DNA binding; the SUMO E3 ligase activity of PIAS1 is dispensable for its role in myogenic differentiation. Reporter assays, RNAi knockdown, overexpression, DNA binding assays, SUMO ligase-dead mutant analysis Molecular and cellular biology Medium 19620279
2009 PIAS1 and PIAS4 are recruited to DNA double-strand break sites via their SAP domains and are required for SUMO1 and SUMO2/3 accumulation at DSB sites; they promote the productive association of 53BP1, BRCA1, and RNF168 with damage sites and are required for ubiquitin adduct formation by RNF8, RNF168, and BRCA1, ultimately promoting DSB repair and conferring ionizing radiation resistance. Laser micro-irradiation/IRIF assays, SAP domain mutants, siRNA knockdown, epistasis with E3 ligases, repair assays Nature High 20016603
2010 PIAS1 restricts natural T regulatory (Treg) cell differentiation by maintaining repressive chromatin at the Foxp3 promoter; PIAS1 binds the Foxp3 promoter and recruits DNA methyltransferases and heterochromatin protein 1 (HP1) for epigenetic modifications; Pias1 deletion causes promoter demethylation, reduced H3K9 methylation, and increased Treg numbers in vivo. Knockout mouse, ChIP, bisulfite sequencing, chromatin accessibility assays, flow cytometry Science High 20966256
2010 PIAS1 suppresses TGFβ-induced EMT in mammary epithelial cells in a SUMO ligase-dependent manner; TGFβ downregulates PIAS1 levels during EMT; PIAS1 sumoylates SnoN, and loss of SnoN sumoylation impairs its ability to inhibit TGFβ-induced EMT. Gain/loss-of-function (overexpression and siRNA), sumoylation assays, mutagenesis of SnoN sumoylation sites, morphological EMT readouts PloS one Medium 21103059
2010 PIAS1 promotes sumoylation of the Gli transcription factors downstream of Hedgehog signaling; expression of SUMO-1 or PIAS1 increases Gli transcriptional activity in vitro; in the embryonic neural tube, forced PIAS1 expression increases Gli activity and induces ectopic Nkx2.2, while a ligase-dead PIAS1 mutant blocks endogenous Nkx2.2 expression. Cell-based SUMOylation assays, reporter assays, in ovo electroporation in embryonic neural tube, PIAS1 ligase-dead mutant PloS one Medium 20711444
2010 PIAS1 regulates subnuclear localization of CP2c and forms a stable hexameric DNA-binding complex with CP2c and CP2b on the α-globin promoter; PIAS1 acts as a SUMO-independent co-activator by bridging two CP2 proteins through distinct interaction domains; PIAS1 knockdown reduces both CP2c and CP2b promoter occupancy. RNAi knockdown, in vitro DNA binding (EMSA), coimmunoprecipitation, ChIP, nuclear localization assays, domain mapping Nucleic acids research Medium 20421208
2011 PIAS1 couples ROS-dependent JNK activation to the SUMO pathway: PIAS1 knockdown prevents ROS-induced hypersumoylation and also enhances JNK signaling; conversely, PIAS1 overexpression inhibits JNK activity independently of its SUMO ligase function, indicating a non-enzymatic function in JNK regulation; PIAS1 knockdown attenuates ROS-dependent apoptosis. siRNA knockdown, overexpression, JNK activity assays, SUMO ligase-dead mutants, caspase-3/7 activity assays, transcriptomic profiling FASEB journal Medium 21676946
2012 PIAS1 sumoylates PML to promote its CK2-mediated phosphorylation and subsequent ubiquitin/proteasome-mediated degradation, attenuating PML tumor suppressor function; PIAS1-mediated sumoylation of PML-RARA is essential for arsenic trioxide-induced degradation of PML-RARA and apoptosis in APL cells. Co-IP, SUMOylation assays, proteasome inhibitor studies, siRNA knockdown, apoptosis assays Cancer research Medium 22406621
2012 PIAS1 sumoylates SATB1 at Lys-744, and this sumoylation regulates caspase-6-mediated cleavage of SATB1 at PML nuclear bodies; phosphorylation of SATB1 at Thr-188 inhibits its interaction with the PIAS1 SAP motif and thereby blocks sumoylation; an LXXLL motif (residues 193–197) near the phosphorylation site mediates interaction with the PIAS SAP domain. Mutagenesis, coimmunoprecipitation, in vitro binding, cell-based sumoylation and cleavage assays Molecular and cellular biology Medium 20351170
2012 PIAS1 is phosphorylated at Ser522 by MAPK-activated protein kinase-2 (MK2); this phosphorylation enhances both PIAS1 SUMO E3 ligase activity (toward p53) and its transrepression activity; PIAS1-S522A mutant fails to promote p53 sumoylation or exert anti-inflammatory effects in endothelial cells in vitro and in vivo. Phosphomutant analysis (S522A), in vivo p53 sumoylation assay, reporter assays, leukocyte rolling in microvessels (in vivo) Arteriosclerosis, thrombosis, and vascular biology Medium 23202365
2013 PIAS1 is an E3 SUMO ligase for both Huntingtin (HTT) SUMO-1 and SUMO-2 modification; PIAS1-mediated SUMO-2 modification regulates the accumulation of insoluble HTT; overexpression of PIAS1 increases and knockdown decreases insoluble HTT accumulation; reduction of dPIAS in a mutant HTT Drosophila model is protective. Systematic E3 SUMO ligase screen, siRNA knockdown, overexpression, insolubility fractionation assays, Drosophila model Cell reports High 23871671
2013 PIAS1 functions as a SUMO E3 ligase for C/EBPβ through its SAP domain interaction; PIAS1-mediated sumoylation of C/EBPβ promotes its ubiquitination and proteasomal degradation; PIAS1 expression transiently peaks on day 4 of adipocyte differentiation when C/EBPβ declines, and PIAS1 inhibits adipogenesis in a catalytic activity-dependent manner. Coimmunoprecipitation, in vitro and in vivo sumoylation assays, ubiquitination assays, protein stability assays, RNAi, overexpression, adipogenesis assays Molecular and cellular biology High 24061474
2013 PIAS1 forms a non-covalent ternary complex with SUMO1 and UBC9, in addition to the canonical E2–E3 interaction; SUMO acts as a bridge with non-overlapping interfaces for UBC9 and PIAS1; phosphorylation of serine residues adjacent to the PIAS1 SIM favors this ternary complex; the ternary complex is required for PIAS1/SUMO1-mediated transcriptional repression. Bioluminescence resonance energy transfer (BRET), NMR spectroscopy, isothermal titration calorimetry, biochemical binding assays, functional transcriptional repression assays The Journal of biological chemistry High 24174529
2013 PIAS1 is a component of the transcription-coupled DNA damage repair complex containing PNKP (polynucleotide kinase-phosphatase) and functions as a SUMO E3 ligase for PNKP; PIAS1 knockdown restores mutant HTT-perturbed PNKP enzymatic activity. Co-immunoprecipitation of repair complex, SUMOylation assay for PNKP, PNKP activity assay after PIAS1 knockdown Proceedings of the National Academy of Sciences of the United States of America Medium 33468657
2014 PIAS1 SUMOylates RUNX family members (RUNX1, RUNX2, RUNX3) at a conserved lysine residue; PIAS1-mediated sumoylation inhibits RUNX3 transactivation activity; this modification is promoted by AKT1 kinase; in nude mice, a RUNX3 sumoylation-site mutant promotes tumorigenicity compared to wild-type RUNX3. Drosophila genetic screen, cell-based sumoylation assays, mutagenesis, reporter assays, in vivo xenograft tumor model Oncogenesis Medium 24777122
2014 PIAS1 sumoylates CREB1Δ (short isoform) at Lys-271 and Lys-290, increasing CREB1Δ protein levels; CREB sumoylation in rat CA1 neurons is increased by water maze training; lentiviral transduction of sumoylation-deficient CREB (K271R/K290R) into CA1 impairs spatial memory, while PIAS1 siRNA knockdown in CA1 decreases endogenous CREB sumoylation and impairs spatial memory. In vitro and in vivo sumoylation assays, mutagenesis, lentiviral gene transfer, in vivo water maze, ChIP for BDNF promoter The Journal of neuroscience Medium 25031400
2014 PIAS1 functions as a chromatin-bound AR coregulator on prostate cancer cell chromatin; ChIP-seq shows PIAS1 occupies AR chromatin binding sites enriched with SUMO2/3 and H3K4me2; androgen exposure increases PIAS1 chromatin occupancy to overlap nearly completely with AR; PIAS1 also interacts with the pioneer factor FOXA1; PIAS1 depletion affects AR chromatin occupancy at sites enriched for HOXD13 and GATA motifs. ChIP-seq, RNAi, transcriptome analysis, coimmunoprecipitation Nucleic acids research High 25552417
2014 PIAS1 promotes lymphomagenesis by SUMOylating MYC; PIAS1-mediated SUMOylation promotes MYC phosphorylation at Ser62 and dephosphorylation at Thr58, reducing MYC turnover and increasing its transcriptional activity; Pias1-null mice display endothelial defects reminiscent of Myc-null mice. Coimmunoprecipitation, cell-based sumoylation assay, phosphorylation analysis, MYC stability/turnover assays, siRNA knockdown, Pias1-null mice Cell reports Medium 27239040
2015 PIAS1 is the SUMO E3 ligase that mediates c-Myc SUMOylation; PIAS1 knockdown reduces c-Myc SUMOylation and increases c-Myc transcriptional activity; SUMOylated c-Myc is subsequently ubiquitylated by RNF4 and degraded by the proteasome; 10 SUMO acceptor lysines on c-Myc were identified by mass spectrometry. siRNA knockdown, in vivo sumoylation assay, mass spectrometry, mutagenesis, ubiquitination assay, transcriptional activity assays Cell cycle Medium 25895136
2015 PIAS1-mediated sumoylation of TRF2 triggers its proteasomal degradation: TRF2 interacts with PIAS1 in mammalian cells and is sumoylated by PIAS1; SUMO-conjugated TRF2 is recognized by the STUbL RNF4, which ubiquitinates it; proteasome inhibition stabilizes SUMO-conjugated but not unmodified TRF2. Coimmunoprecipitation, in vivo sumoylation assay, ubiquitination assay, proteasome inhibitor experiments FEBS letters Medium 26450775
2015 In fission yeast, the PIAS1 ortholog Pli1 is stabilized by Ulp1-mediated desumoylation; delocalized Ulp1 leads to SUMO chain modification of Pli1 and its subsequent proteasomal degradation via the STUbL/Cdc48-Ufd1-Npl4 pathway, causing profound SUMO pathway defects and centromere dysfunction. Genetic yeast mutants, protein stability assays, proteasome inhibitors, SUMOylation assays in fission yeast The Journal of biological chemistry Medium 26221037
2016 PIAS1 reduction in mouse striatum via intrastriatal miRNA injection reduces mHTT accumulation, SUMO- and ubiquitin-modified protein accumulation, and improves behavioral phenotypes in R6/2 HD mice; conversely, PIAS1 overexpression exacerbates mHTT accumulation and phenotypes. In vivo miRNA knockdown in R6/2 mice, intrastriatal injection, behavioral testing, biochemical fractionation, histology Neuron High 27146268
2016 PIAS1 constitutively localizes at PML nuclear bodies in a SUMO interaction motif (SIM)-dependent manner requiring SUMOylated/sumoylation-competent PML; upon HSV-1 infection, PIAS1 is recruited to nuclear sites of viral genome entry in a SIM-dependent, PML-enhanced manner, promotes SUMO1 accumulation at those sites, and cooperatively restricts HSV-1 replication; the viral E3 ligase ICP0 antagonizes PIAS1 recruitment. Immunofluorescence localization, SIM mutant analysis, siRNA knockdown, viral replication assays, colocalization with viral genome sites Journal of virology Medium 27099310
2016 PIAS1 inhibits EBV lytic replication and is cleaved by caspases upon lytic triggers (BCR activation, chemical induction); caspase-mediated cleavage of PIAS1 abolishes its restriction activity; a cleavage-resistant PIAS1 mutant suppresses EBV replication; mechanistically, PIAS1 acts as an inhibitor of transcription factors required for lytic gene expression. PIAS1 knockdown/reconstitution, caspase inhibitor experiments, cleavage-resistant mutant, EBV lytic gene expression analysis Cell reports Medium 29262325
2018 PIAS1 and PIAS4 promote PCNA sumoylation at Lys-164 during normal cell cycle; PIAS1/PIAS4 double-deficient cells show >90% decrease in PCNA Lys-164 sumoylation and >90% decrease in error-free template switch DNA damage tolerance; the PCNA mutation is epistatic with PIAS1/PIAS4 mutation, indicating their action is through PCNA sumoylation. PIAS1/PIAS4 knockout DT40 and human TK6 cells, Ig gene conversion assay (template switch readout), PCNA sumoylation assay, epistasis with PCNA mutant, PCNA-SUMO1 chimera rescue Proceedings of the National Academy of Sciences of the United States of America High 30487218
2018 PIAS1 acts as a specific E3 SUMO ligase for PPARγ in cardiomyocytes; PIAS1-mediated PPARγ sumoylation represses NF-κB activity; PIAS1 deficiency aggravates ischemia/reperfusion injury-induced apoptosis and inflammation in cardiomyocytes via NF-κB pathway activation. Co-IP, in vivo sumoylation assay, siRNA knockdown, overexpression, apoptosis and inflammatory assays, mouse I/R model BMC cell biology Medium 30419807
2019 PIAS1 is modified by SUMO3, and SUMO3-modified PIAS1 mediates AR cytoplasmic translocation, ubiquitination by MDM2, and proteasomal degradation; the SUMO-acceptor Lys-117 on PIAS1 is essential for AR translocation; PIAS1/SUMO3 promotes interaction between sumoylated PIAS1 and AR Lys-386/Lys-845 to form a binary complex that recruits MDM2 for AR ubiquitination. Coimmunoprecipitation, sumoylation assay, PIAS1 mutagenesis, immunostaining for AR localization, ubiquitination assay, MDM2 interaction Cell communication and signaling Medium 31752909
2020 PIAS1 sumoylates vimentin (VIM) at Lys-439 and Lys-445; VIM sumoylation is necessary for dynamic vimentin disassembly, and cells expressing non-SUMOylatable VIM show reduced cell migration; quantitative SUMO proteomics identified 62 putative PIAS1 substrates across diverse cellular pathways. Quantitative SUMO proteomics (SILAC-based), in vivo sumoylation assay, mutagenesis of VIM sumoylation sites, cell migration assays Nature communications High 32047143
2021 PIAS1 promotes SUMOylation of the m6A reader YTHDF2 at Lys-281, Lys-571, and Lys-572; YTHDF2 lacking sumoylation shows reduced binding to EBV transcripts and reduced EBV mRNA decay; PIAS1 synergizes with wild-type but not sumoylation-deficient YTHDF2 to limit EBV lytic replication; PIAS1 also sumoylates YTHDF1 and YTHDF3. Coimmunoprecipitation, in vivo sumoylation assay, mutagenesis, RNA binding assays, viral replication assays mBio Medium 38236021
2021 SLX4IP recruits PIAS1 to the SLX4 complex and activates its E3 SUMO ligase activity; PIAS1 sumoylates the telomere protein RAP1, disrupting its interaction with TRF2 and facilitating RAP1 nucleocytoplasmic shuttling; cytosolic RAP1 then binds IKK, activating NF-κB and inducing Jagged-1/Notch signaling to institute the ALT telomere maintenance pathway. Coimmunoprecipitation, SUMOylation assay, RAP1 localization tracking, NF-κB reporter assays, ALT assays Science signaling Medium 34187905
2022 PIAS1 interacts with influenza A virus polymerase subunit PB2 and catalyzes robust PB2 sumoylation, reducing PB2 stability; PIAS1 SUMO E3 ligase activity is required to inhibit viral RNP complex activity; PIAS1 knockdown/knockout increases IAV growth and virulence in mice, while overexpression suppresses replication. Coimmunoprecipitation, siRNA knockdown, CRISPR/Cas9 knockout, overexpression, RNP activity assay, SUMO ligase-dead mutant (C351S, W372A), protein stability assay, in vivo mouse model PLoS pathogens High 35377920
2014 Necdin binds PIAS1 central conserved domains and suppresses PIAS1-dependent sumoylation of substrates STAT1 and PML; necdin promotes ubiquitin-proteasome-mediated degradation of PIAS1 specifically within the nuclear matrix. Coimmunoprecipitation, sumoylation assays, ubiquitination/proteasome assays, nuclear matrix fractionation, PIAS1 terminal deletion mutants PloS one Medium 24911587
2013 PIAS1 interacts with STI1 (stress-inducible phosphoprotein 1) through aa 450–480 of PIAS1 (mapped by surface plasmon resonance and yeast two-hybrid); PIAS1 overexpression promotes STI1 nuclear retention and co-directs STI1 and Hsp90 to specific sub-nuclear regions; PIAS1 can act as a SUMO E3 ligase for STI1 (5 sites identified by MS), but PIAS1-mediated nuclear retention of STI1 can occur through direct interaction even with non-sumoylatable STI1; PIAS1 knockdown impairs radiation-induced nuclear STI1 accumulation. Yeast two-hybrid, surface plasmon resonance, coimmunoprecipitation, mass spectrometry of SUMOylation sites, RNAi, subcellular fractionation/localization assays Molecular & cellular proteomics Medium 23938469
2020 PIAS1 and TIF1γ form a trimeric complex with SnoN to collaboratively promote SnoN SUMOylation and suppress EMT; PIAS1 and TIF1γ act in an interdependent (not additive) manner for EMT suppression in breast organoids. Coimmunoprecipitation of trimeric complex, SUMOylation assay, loss-of-function (siRNA), 3D breast organoid EMT assay Cell death and differentiation Medium 32770107

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Inhibition of Stat1-mediated gene activation by PIAS1. Proceedings of the National Academy of Sciences of the United States of America 586 9724754
2009 Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 441 20016603
2001 Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Molecular cell 408 11583632
2002 Transcription factor Sp3 is silenced through SUMO modification by PIAS1. The EMBO journal 226 12356736
2004 PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nature immunology 210 15311277
2002 PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. The Journal of biological chemistry 188 12177000
2007 Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 135 17540171
2005 Negative regulation of NF-kappaB signaling by PIAS1. Molecular and cellular biology 134 15657437
2013 SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell reports 96 23871671
2012 The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer research 94 22406621
2010 The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science (New York, N.Y.) 90 20966256
2015 c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell cycle (Georgetown, Tex.) 88 25895136
2003 PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. The Journal of biological chemistry 87 14500712
2000 Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proceedings of the National Academy of Sciences of the United States of America 85 10805787
2006 PIAS1 confers DNA-binding specificity on the Msx1 homeoprotein. Genes & development 82 16600910
2016 PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron 74 27146268
2004 PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Molecular and cellular biology 74 15572666
2002 Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). The Journal of biological chemistry 74 11788578
2007 Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proceedings of the National Academy of Sciences of the United States of America 72 17606919
2004 NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers. The Journal of biological chemistry 72 15133049
2004 DNA cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation. Molecular and cellular biology 70 15572677
2020 Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility. Nature communications 69 32047143
2012 PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. The American journal of pathology 69 22449952
2005 Pias1 interaction and sumoylation of metabotropic glutamate receptor 8. The Journal of biological chemistry 60 16144832
2008 Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends in pharmacological sciences 57 18755518
2009 SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway. Molecular and cellular biology 55 19620279
2011 The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 54 21676946
2014 SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic acids research 52 25552417
2013 Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis. Molecular and cellular biology 52 24061474
1997 Cloning and characterization of Gu/RH-II binding protein. Biochemical and biophysical research communications 52 9177271
2014 SUMOylation by the E3 ligase TbSIZ1/PIAS1 positively regulates VSG expression in Trypanosoma brucei. PLoS pathogens 48 25474309
2011 mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. Journal of the National Cancer Institute 47 21862729
2010 Suppression of TGFβ-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. PloS one 46 21103059
2005 PIAS1 activates the expression of smooth muscle cell differentiation marker genes by interacting with serum response factor and class I basic helix-loop-helix proteins. Molecular and cellular biology 46 16135793
2000 In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. The Journal of clinical investigation 46 10930443
2016 SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1. Journal of virology 44 27099310
2009 PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling. Genes & development 43 19136629
2021 PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 41 33468657
2004 FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocrine research 41 15666801
2024 Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1. Molecular cancer 40 39334380
2014 CREB SUMOylation by the E3 ligase PIAS1 enhances spatial memory. The Journal of neuroscience : the official journal of the Society for Neuroscience 40 25031400
2016 PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell reports 39 27239040
2010 SUMOylation by Pias1 regulates the activity of the Hedgehog dependent Gli transcription factors. PloS one 39 20711444
2017 Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer. PloS one 36 28493978
2015 Protein Inhibitor of Activated STAT 1 (PIAS1) Protects Against Obesity-Induced Insulin Resistance by Inhibiting Inflammation Cascade in Adipose Tissue. Diabetes 36 26324179
2017 B Cell Receptor Activation and Chemical Induction Trigger Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Reactivation. Cell reports 35 29262325
2009 Substantially reduced expression of PIAS1 is associated with colon cancer development. Journal of cancer research and clinical oncology 35 19288270
2022 PIAS1-mediated SUMOylation of influenza A virus PB2 restricts viral replication and virulence. PLoS pathogens 34 35377920
2018 SUMOylation of PCNA by PIAS1 and PIAS4 promotes template switch in the chicken and human B cell lines. Proceedings of the National Academy of Sciences of the United States of America 34 30487218
2003 PIAS1 enhances SUMO-1 modification and the transactivation activity of the major immediate-early IE2 protein of human cytomegalovirus. FEBS letters 34 14644436
2018 PIAS1 protects against myocardial ischemia-reperfusion injury by stimulating PPARγ SUMOylation. BMC cell biology 33 30419807
2016 Specific regulation of PRMT1 expression by PIAS1 and RKIP in BEAS-2B epithelia cells and HFL-1 fibroblasts in lung inflammation. Scientific reports 33 26911452
2010 Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1. Molecular and cellular biology 33 20351170
2014 PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PloS one 32 24586797
2014 PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget 32 25474038
2007 TGF-beta suppresses IFN-gamma-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes/macrophages. Journal of immunology (Baltimore, Md. : 1950) 32 17371985
2014 A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis. Oncoscience 31 25594015
2014 RUNX family members are covalently modified and regulated by PIAS1-mediated sumoylation. Oncogenesis 30 24777122
2008 Functional interaction of AIRE with PIAS1 in transcriptional regulation. Molecular immunology 28 18083234
2007 PIAS1 interacts with and represses SOX9 transactivation activity. Molecular reproduction and development 28 17440973
2016 PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia (New York, N.Y.) 26 27237320
2013 PIAS1 SUMO ligase regulates the self-renewal and differentiation of hematopoietic stem cells. The EMBO journal 26 24357619
2019 Interaction of PIAS1 with PRRS virus nucleocapsid protein mediates NF-κB activation and triggers proinflammatory mediators during viral infection. Scientific reports 24 31363150
2013 Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation. The Journal of biological chemistry 24 24174529
2015 Pli1(PIAS1) SUMO ligase protected by the nuclear pore-associated SUMO protease Ulp1SENP1/2. The Journal of biological chemistry 23 26221037
2013 Regulation of stress-inducible phosphoprotein 1 nuclear retention by protein inhibitor of activated STAT PIAS1. Molecular & cellular proteomics : MCP 23 23938469
2013 PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis. Cell death & disease 23 24052079
2011 PIAS1 interacts with FLASH and enhances its co-activation of c-Myb. Molecular cancer 23 21338522
2003 Expression of the E3 SUMO-1 ligases PIASx and PIAS1 during spermatogenesis in the rat. Gene expression patterns : GEP 23 12799075
2024 SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication. mBio 22 38236021
2019 SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability. Cell communication and signaling : CCS 22 31752909
2013 PIAS1 negatively modulates virus triggered type I IFN signaling by blocking the DNA binding activity of IRF3. Antiviral research 22 24036127
2012 The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1. Biology of the cell 22 22283414
2021 Silencing miR-181b-5p upregulates PIAS1 to repress oxidative stress and inflammatory response in rats with alcoholic fatty liver disease through inhibiting PRMT1. International immunopharmacology 21 34836796
2021 PIAS1 alleviates diabetic peripheral neuropathy through SUMOlation of PPAR-γ and miR-124-induced downregulation of EZH2/STAT3. Cell death discovery 21 34857740
2012 Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arteriosclerosis, thrombosis, and vascular biology 21 23202365
2021 SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-κB and Notch signaling. Science signaling 20 34187905
2006 Overexpression of the mTOR alpha4 phosphoprotein activates protein phosphatase 2A and increases Stat1alpha binding to PIAS1. Molecular and cellular endocrinology 20 17084018
2012 A role for protein inhibitor of activated STAT1 (PIAS1) in lipogenic regulation through SUMOylation-independent suppression of liver X receptors. The Journal of biological chemistry 19 22969086
2020 TRIM59 suppresses NO production by promoting the binding of PIAS1 and STAT1 in macrophages. International immunopharmacology 18 33045573
2012 The SUMO ligase PIAS1 regulates UV-induced apoptosis by recruiting Daxx to SUMOylated foci. Journal of cell science 18 22976298
2011 Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1. Endocrinology 18 21467194
2021 PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation. Cell & bioscience 16 34238351
2016 Pias1 is essential for erythroid and vascular development in the mouse embryo. Developmental biology 16 27155222
2011 Upregulation of PIAS1 protects against sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury. Cytokine 16 21419645
2007 Interaction between GATA-3 and the transcriptional coregulator Pias1 is important for the regulation of Th2 immune responses. Journal of immunology (Baltimore, Md. : 1950) 16 18056374
2005 Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net. Oncogene 16 15580297
2014 Potentiation of Tbx5-mediated transactivation by SUMO conjugation and protein inhibitor of activated STAT 1 (PIAS1). The international journal of biochemistry & cell biology 15 24582888
2014 Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase. PloS one 15 24911587
2015 PIAS1-mediated sumoylation promotes STUbL-dependent proteasomal degradation of the human telomeric protein TRF2. FEBS letters 14 26450775
2014 High mobility group nucleosomal binding domain 2 (HMGN2) SUMOylation by the SUMO E3 ligase PIAS1 decreases the binding affinity to nucleosome core particles. The Journal of biological chemistry 14 24872413
2013 The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 14 23472246
2010 PIAS1 regulates CP2c localization and active promoter complex formation in erythroid cell-specific alpha-globin expression. Nucleic acids research 14 20421208
2007 The transcriptional repression activity of KyoT2 on the Notch/RBP-J pathway is regulated by PIAS1-catalyzed SUMOylation. Journal of molecular biology 14 17509614
2007 PIAS1 interacts with the KRAB zinc finger protein, ZNF133, via zinc finger motifs and regulates its transcriptional activity. Experimental & molecular medicine 14 17934332
2020 PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition. Cell death and differentiation 13 32770107
2016 PIAS1 binds p300 and behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO-status. Biochimica et biophysica acta 13 27032383
2010 SiRNA-mediated PIAS1 silencing promotes inflammatory response and leads to injury of cerulein-stimulated pancreatic acinar cells via regulation of the P38MAPK signaling pathway. International journal of molecular medicine 13 20818504
2021 The E3 Ligase PIAS1 Regulates p53 Sumoylation to Control Stress-Induced Apoptosis of Lens Epithelial Cells Through the Proapoptotic Regulator Bax. Frontiers in cell and developmental biology 12 34195189
2020 SUMO E3 ligase PIAS1 is a potential biomarker indicating stress susceptibility. Psychoneuroendocrinology 12 32688147

Missed literature

Know a paper Affinage missed for PIAS1? Flag it for the maintainers and the community.

No submissions yet.